Free Trial

Millennium Management LLC Decreases Stock Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Cellebrite DI logo with Business Services background

Millennium Management LLC decreased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 20.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,182,701 shares of the company's stock after selling 298,527 shares during the quarter. Millennium Management LLC owned 0.57% of Cellebrite DI worth $26,055,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. True Wind Capital Management L.P. raised its position in Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after buying an additional 2,130,386 shares during the last quarter. FMR LLC raised its position in Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after buying an additional 5,004,587 shares during the last quarter. Axon Enterprise Inc. purchased a new position in Cellebrite DI in the 4th quarter worth about $198,270,000. Voss Capital LP raised its position in Cellebrite DI by 1.2% in the 4th quarter. Voss Capital LP now owns 3,240,000 shares of the company's stock worth $71,377,000 after buying an additional 39,700 shares during the last quarter. Finally, Pertento Partners LLP raised its position in Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock worth $65,547,000 after buying an additional 626,373 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.

Wall Street Analyst Weigh In

CLBT has been the subject of a number of recent research reports. Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Needham & Company LLC cut their price target on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, JPMorgan Chase & Co. cut their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $22.43.

Get Our Latest Analysis on Cellebrite DI

Cellebrite DI Trading Down 2.2%

NASDAQ CLBT opened at $17.02 on Tuesday. The stock has a market cap of $4.08 billion, a PE ratio of -12.24, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The stock's 50 day moving average is $19.01 and its 200 day moving average is $20.25.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The company's revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 EPS. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

(Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Read More

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cellebrite DI Right Now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines